Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose ulinastatin for SIRS relief in acute pancreatitis (ChiCTR2300072139)
ChiCTR2300072139Phase 4Recruiting
- Sponsor
- Changhai Hospital
- Start
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in acute pancreatitis (AP) comparing High-dose ulinastatin group with Placebo control group (2 arms). Primary endpoint: SIRS relief rate on day 5. Started Jun 2023; status: recruiting.
02
Drugs
ulinastatin
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on ChiCTR2300072139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072139.